Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03001076 · ClinicalTrials.gov registry record · Phase 3

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

A Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by Esperion Therapeutics.

Completed
Registry status
Phase 3
Development phase
269
Enrollment target
1
Study location

NCT03001076 is a Phase 3 study of Atherosclerosis and Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 269 participants, below the 1,062-participant average among 69 other Atherosclerosis trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03001076, a Phase 3 study of Atherosclerosis and Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
269 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

Conditions Studied

Atherosclerosis Hypercholesterolemia Statin Adverse Reaction

Interventions

  • OTHER Placebo
  • DRUG Ezetimibe
  • DRUG Bempedoic acid

Study Locations (1)

Texas

  • - Georgetown

Trial Details

FieldValue
Enrollment Target 269 participants
Start Date 2016-11-29
Est. Completion 2018-02-12
Phase Phase 3

Sponsor

Esperion Therapeutics

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03001076

The ClinicalTrials.gov registry entry for NCT03001076 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,062-participant average among 69 other Atherosclerosis trials with a reported enrollment target (75% lower). The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03001076 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03001076 about?

NCT03001076 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)". The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.

What is the current status of trial NCT03001076?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2016-11-29. Estimated completion is 2018-02-12.

What conditions does trial NCT03001076 study?

This clinical trial studies the following conditions: Atherosclerosis, Hypercholesterolemia, Statin Adverse Reaction.

What interventions are being tested in trial NCT03001076?

The interventions under investigation include: Placebo (OTHER), Ezetimibe (DRUG), Bempedoic acid (DRUG).

Who is sponsoring clinical trial NCT03001076?

This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03001076 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atherosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atherosclerosis

All registered trials for this condition

Hypercholesterolemia

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.